KR102444718B1 - 아미노산 유도체의 전구약물 - Google Patents

아미노산 유도체의 전구약물 Download PDF

Info

Publication number
KR102444718B1
KR102444718B1 KR1020187029353A KR20187029353A KR102444718B1 KR 102444718 B1 KR102444718 B1 KR 102444718B1 KR 1020187029353 A KR1020187029353 A KR 1020187029353A KR 20187029353 A KR20187029353 A KR 20187029353A KR 102444718 B1 KR102444718 B1 KR 102444718B1
Authority
KR
South Korea
Prior art keywords
carbonyl
oxy
hexane
group
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187029353A
Other languages
English (en)
Korean (ko)
Other versions
KR20180134892A (ko
Inventor
노리카즈 오타케
다카시 하시하야타
요헤이 마츠다
세이지 마스다
유코 야마우치
Original Assignee
다이쇼 세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다이쇼 세이야꾸 가부시끼가이샤 filed Critical 다이쇼 세이야꾸 가부시끼가이샤
Publication of KR20180134892A publication Critical patent/KR20180134892A/ko
Application granted granted Critical
Publication of KR102444718B1 publication Critical patent/KR102444718B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/48—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing ten carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
KR1020187029353A 2016-04-18 2017-04-18 아미노산 유도체의 전구약물 Active KR102444718B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016083147 2016-04-18
JPJP-P-2016-083147 2016-04-18
PCT/JP2017/016125 WO2017183734A1 (en) 2016-04-18 2017-04-18 Prodrug of amino acid derivative

Publications (2)

Publication Number Publication Date
KR20180134892A KR20180134892A (ko) 2018-12-19
KR102444718B1 true KR102444718B1 (ko) 2022-09-16

Family

ID=58737797

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187029353A Active KR102444718B1 (ko) 2016-04-18 2017-04-18 아미노산 유도체의 전구약물

Country Status (29)

Country Link
US (2) US10464884B2 (enExample)
EP (1) EP3445743B1 (enExample)
JP (2) JP7045321B2 (enExample)
KR (1) KR102444718B1 (enExample)
CN (1) CN109071418B (enExample)
AU (1) AU2017254266B2 (enExample)
BR (1) BR112018069959B1 (enExample)
CA (1) CA3019097C (enExample)
CY (1) CY1124574T1 (enExample)
DK (1) DK3445743T3 (enExample)
ES (1) ES2886442T3 (enExample)
HR (1) HRP20211277T1 (enExample)
HU (1) HUE056046T2 (enExample)
IL (1) IL262233B (enExample)
LT (1) LT3445743T (enExample)
MX (1) MX379567B (enExample)
MY (1) MY195208A (enExample)
NZ (1) NZ747061A (enExample)
PH (1) PH12018502211A1 (enExample)
PL (1) PL3445743T3 (enExample)
PT (1) PT3445743T (enExample)
RS (1) RS62515B1 (enExample)
RU (1) RU2739318C2 (enExample)
SG (2) SG11201808387PA (enExample)
SI (1) SI3445743T1 (enExample)
SM (1) SMT202100601T1 (enExample)
TW (1) TWI738767B (enExample)
WO (1) WO2017183734A1 (enExample)
ZA (1) ZA201806444B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY195208A (en) * 2016-04-18 2023-01-11 Taisho Pharmaceutical Co Ltd Prodrug of Amino Acid Derivative
JP7314494B2 (ja) * 2017-10-17 2023-07-26 大正製薬株式会社 アミノ酸誘導体のプロドラッグを含有する医薬
JP7436385B2 (ja) * 2018-04-24 2024-02-21 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド Ｈｉｖ成熟阻害活性を有する化合物
CN109180712B (zh) * 2018-08-08 2020-12-25 南京医科大学 一类2-茨醇的芳基硼酸酯衍生物及其应用
CN108948077B (zh) * 2018-08-09 2020-10-13 东华理工大学 一种α-磷酰化的α-氨基酸酯类化合物及其合成方法
JPWO2022114135A1 (enExample) * 2020-11-26 2022-06-02
CN112409443B (zh) * 2021-01-25 2021-04-27 潍坊科技学院 一种脯氨酸茨醇衍生物及其制备方法和在制备治疗心脑血管类疾病的药物中的应用
CN114805104B (zh) * 2021-01-29 2026-06-30 南京宁丹新药技术股份有限公司 一类氨基水杨酸类衍生物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045898A1 (en) 2001-11-23 2003-06-05 Eli Lilly And Company Prodrugs of excitatory amino acids
WO2012068041A1 (en) 2010-11-18 2012-05-24 Eli Lilly And Company 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL208123B1 (pl) 2001-12-27 2011-03-31 Taisho Pharmaceutical Co Ltd Pochodna kwasu 2-amino-3-alkoksy-6-fluorobicyklo [3.1.0] heksano-2, 6-dikarboksylowego, zawierająca ją kompozycja farmaceutyczna i lek, oraz jej zastosowanie
EP2123630B1 (en) 2003-06-26 2012-07-25 Taisho Pharmaceutical Co., Ltd 2-Amino-bicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative
US8642777B2 (en) 2009-11-19 2014-02-04 Taisho Pharmaceutical Co., Ltd Process for producing 3-alkoxy-2-amino-6-fluorobicyclo [3.1.0] hexane-2,6-dicarboxylic acid derivative and intermediate thereof
AR083845A1 (es) 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
WO2013062680A1 (en) 2011-10-25 2013-05-02 Braincells, Inc. Novel compounds and compositions thereof for treating nervous system disorders
EP2857385B1 (en) * 2012-06-01 2017-08-02 Taisho Pharmaceutical Co., Ltd. Prodrug of fluorine-containing amino acid
WO2015065983A1 (en) 2013-10-29 2015-05-07 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of gastrointestinal infections
MY195208A (en) * 2016-04-18 2023-01-11 Taisho Pharmaceutical Co Ltd Prodrug of Amino Acid Derivative

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045898A1 (en) 2001-11-23 2003-06-05 Eli Lilly And Company Prodrugs of excitatory amino acids
WO2012068041A1 (en) 2010-11-18 2012-05-24 Eli Lilly And Company 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Yasuhara, Akito et al., Bioorganic & Medicinal Chemistry, 2006, vol.14, p.4193-4207

Also Published As

Publication number Publication date
US10464884B2 (en) 2019-11-05
PT3445743T (pt) 2021-08-24
AU2017254266B2 (en) 2021-03-11
SG11201808387PA (en) 2018-10-30
CY1124574T1 (el) 2022-07-22
WO2017183734A1 (en) 2017-10-26
US20190047943A1 (en) 2019-02-14
MX379567B (es) 2025-03-11
HRP20211277T1 (hr) 2021-11-12
RU2739318C2 (ru) 2020-12-22
US20190337887A1 (en) 2019-11-07
PL3445743T3 (pl) 2021-12-20
SI3445743T1 (sl) 2021-11-30
EP3445743A1 (en) 2019-02-27
TWI738767B (zh) 2021-09-11
DK3445743T3 (da) 2021-10-18
JP7045321B2 (ja) 2022-03-31
EP3445743B1 (en) 2021-08-04
HUE056046T2 (hu) 2022-01-28
CN109071418A (zh) 2018-12-21
JP2019513755A (ja) 2019-05-30
RU2018140250A3 (enExample) 2020-06-23
BR112018069959A2 (pt) 2019-02-05
ES2886442T3 (es) 2021-12-20
SG10202006019YA (en) 2020-08-28
JP2021063095A (ja) 2021-04-22
MY195208A (en) 2023-01-11
LT3445743T (lt) 2021-09-27
PH12018502211A1 (en) 2019-10-21
ZA201806444B (en) 2020-01-29
AU2017254266A1 (en) 2018-10-25
MX2018012442A (es) 2019-02-21
RS62515B1 (sr) 2021-11-30
BR112018069959B1 (pt) 2023-01-17
RU2018140250A (ru) 2020-05-19
IL262233A (en) 2018-11-29
IL262233B (en) 2021-09-30
CA3019097C (en) 2023-08-29
KR20180134892A (ko) 2018-12-19
US10689327B2 (en) 2020-06-23
SMT202100601T1 (it) 2021-11-12
CN109071418B (zh) 2022-03-18
NZ747061A (en) 2021-07-30
CA3019097A1 (en) 2017-10-26
TW201803842A (zh) 2018-02-01

Similar Documents

Publication Publication Date Title
US10689327B2 (en) Prodrug amino acid derivative
TWI761961B (zh) 稠合吡啶酮類化合物及其製備方法和應用
CA2861150C (en) Morphinan derivative
JP2023502441A (ja) 置換大環状化合物および関連する治療方法
IL259862A (en) Inhibitors of bruton's tyrosine kinase and methods of their use
RU2734475C2 (ru) Разделение энантиомеров 3-этилбицикло [3.2.0] гепт-3-ен-6-она
JP7314494B2 (ja) アミノ酸誘導体のプロドラッグを含有する医薬
HK1260638A1 (en) Prodrug of amino acid derivative
HK1260638B (en) Prodrug of amino acid derivative
JPWO2009093463A1 (ja) 神経細胞死抑制剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181011

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200413

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220222

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220628

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20220914

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20220914

End annual number: 3

Start annual number: 1

PG1601 Publication of registration